As of Oct 02
| +2.72 / +1.51%|
The 22 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 287.50, with a high estimate of 304.00 and a low estimate of 200.00. The median estimate represents a +57.69% increase from the last price of 182.32.
The current consensus among 23 polled investment analysts is to Buy stock in Valeant Pharmaceuticals. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.